"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label merger. Show all posts
Showing posts with label merger. Show all posts

Tuesday, July 16, 2024

STEM Inc. is facing a challenging period, marked by significant revenue declines and strategic adjustments, however, there is real optimism going forward in the energy storage market!

 


In the first quarter of 2024, STEM Inc. reported a 62% year-over-year decrease in revenue, primarily due to a $33 million reduction in revenue from previous periods​ (Stem Investors)​​ (Stem Investors)​. This decline has impacted their gross profit and increased their net loss to $72.3 million compared to $44.8 million in the same quarter of the previous year​ (Stem Investors)​.

Despite these challenges, STEM Inc. has taken steps to improve profitability and focus on higher-margin opportunities. The company has proactively cancelled lower-margin contracts, which has resulted in a reduced backlog but is aimed at improving the overall profitability profile of the company​ (Stem Investors)​. Additionally, STEM has launched new software solutions like the PowerTrack Asset Performance Management suite and Athena PowerBidder Pro, which have been well-received in the market and are expected to drive future growth​ (Stem)​​ (Investing.com)​.

Financially, STEM Inc. has a stable cash position, with $112.8 million in cash and short-term investments at the end of the first quarter of 2024. The company also expects to achieve positive EBITDA for the full year 2024, driven by improved gross margins and cost control measures​ (Stem Investors)​.

There is no specific information about suitors for STEM Inc. at this time. However, the company continues to build strategic partnerships and expand its market presence, which could make it an attractive target in the future​ (Stem)​.

Overall, STEM Inc. is working through its financial difficulties by focusing on higher-margin projects and expanding its innovative software offerings, which may position it for future growth and potential acquisition interest.

STEM Inc. is in a position where several companies could potentially benefit from a merger, particularly those looking to enhance their capabilities in AI-driven clean energy solutions, energy storage, and renewable energy management.

  1. Large Energy Storage and Management Companies: Companies like Fluence and Wartsila, which are heavily involved in large-scale energy storage solutions, could benefit from acquiring STEM Inc. These companies could leverage STEM’s AI-driven software platform, Athena, to optimize their energy storage assets and enhance their software capabilities​ (markets.businessinsider.com)​​ (Energy-Storage.News)​.

  2. Renewable Energy Firms: Renewable energy developers such as NextEra Energy and Enel Green Power might find value in merging with STEM Inc. These firms could integrate STEM’s advanced software solutions to optimize the performance and management of their extensive solar and wind portfolios. This would allow them to enhance their operational efficiency and maximize returns on their renewable energy investments​ (Energy-Storage.News)​​ (Stem Investors)​.

  3. Utility Companies: Major utilities that are expanding their renewable energy and storage projects, such as Duke Energy and Dominion Energy, could also benefit. By incorporating STEM’s technologies, these utilities could improve grid management and reliability, and better integrate distributed energy resources into their systems​ (markets.businessinsider.com)​​ (Stock Analysis)​.

  4. Technology Firms with Clean Energy Focus: Companies like Alphabet (Google) and Amazon, which have significant investments in renewable energy to power their operations, could use STEM’s AI-driven solutions to further optimize their energy usage and enhance sustainability efforts. These technology giants are always looking for innovative solutions to reduce their carbon footprints and improve energy efficiency​ (Energy-Storage.News)​​ (Stem Investors)​.

Potential suitors would not only gain access to STEM’s innovative technology but also benefit from its strong market position and customer base, thereby enhancing their own offerings and competitive edge in the rapidly growing clean energy sector.

The companies best positioned to benefit from a merger with STEM Inc. (STEM) are likely to be large energy storage and management companies, renewable energy firms, and utility companies. Specifically:

  1. Fluence:

    • Strategic Fit: Fluence, a leading global energy storage technology and services provider, would benefit significantly from STEM’s AI-driven software platform, Athena, which optimizes energy storage assets. This integration could enhance Fluence’s offerings in energy storage solutions.
    • Market Position: Fluence’s focus on large-scale energy storage projects aligns well with STEM’s technology and market segment​ (markets.businessinsider.com)​​ (Energy-Storage.News)​.
  2. NextEra Energy:

    • Renewable Energy Expertise: NextEra Energy, one of the largest renewable energy producers, would benefit from STEM’s software solutions to manage and optimize its extensive portfolio of solar and wind projects. This would enhance operational efficiency and financial returns.
    • Sustainability Goals: NextEra’s commitment to sustainability and clean energy makes STEM’s technology a strategic addition to its capabilities​ (Energy-Storage.News)​​ (Stock Analysis)​.
  3. Duke Energy:

    • Utility Integration: Duke Energy, with its focus on expanding renewable energy and storage projects, could leverage STEM’s AI-driven technologies to improve grid management, reliability, and integration of distributed energy resources.
    • Regulatory Compliance: The merger would also help Duke Energy meet regulatory mandates for energy storage and renewable integration more effectively​ (markets.businessinsider.com)​​ (Stem Investors)​.

These companies are well-positioned to integrate STEM’s innovative technology into their existing operations, providing immediate benefits in terms of enhanced efficiency, better asset management, and improved financial performance. 

The strategic alignment of STEM’s AI-driven solutions with these companies' goals and market positions makes them ideal candidates for benefiting from such a merger.

Best bet

A strong argument can be made for Fluence Energy to consider merging with STEM Inc.



We can examine several strategic, operational, and financial factors. Here's a detailed breakdown of the potential advantages and considerations:

Strategic Alignment

  1. Complementary Business Models:

    • Fluence Energy specializes in energy storage and digital applications for renewable energy.
    • STEM Inc. provides AI-driven energy storage solutions and energy management systems.
    • Combining these capabilities could create a comprehensive energy storage and management powerhouse, offering end-to-end solutions.
  2. Market Expansion:

    • A merger could enable both companies to expand their market reach and customer base, leveraging each other's existing networks and market presence.
  3. Technology Synergies:

    • Integrating STEM's AI-driven platform with Fluence's energy storage technology could enhance product offerings, making the combined entity a leader in smart energy solutions.

Operational Efficiency

  1. Cost Savings:

    • Potential for operational efficiencies and cost savings through the consolidation of R&D, administrative functions, and supply chain operations.
    • Economies of scale could reduce production costs and improve margins.
  2. Enhanced Innovation:

    • A merger could facilitate better resource allocation towards innovation, accelerating the development of advanced energy solutions and potentially leading to breakthroughs in energy management technology.

Financial Considerations

  1. Revenue Growth:

    • The combined entity could see significant revenue growth through cross-selling opportunities and expanding service offerings to existing customers.
  2. Market Valuation:

    • A larger, more diversified company might command a higher market valuation, making it more attractive to investors and better positioned to raise capital for future growth.
  3. Cost of Capital:

    • Improved financial stability and market positioning could potentially lower the cost of capital, providing more funds for investment in strategic initiatives.

Competitive Advantage

  1. Stronger Competitive Position:

    • The merger could create a stronger competitor in the energy storage and management sector, capable of competing more effectively against other large players.
  2. Enhanced Customer Value Proposition:

    • By offering a more comprehensive suite of solutions, the combined company could provide greater value to customers, increasing customer loyalty and market share.

Potential Challenges

  1. Integration Risks:

    • Mergers often face integration challenges, including aligning corporate cultures, integrating technology platforms, and retaining key talent.
    • Effective change management and clear communication strategies would be essential to mitigate these risks.
  2. Regulatory Considerations:

    • Regulatory approval processes can be complex and time-consuming. Both companies would need to navigate these processes carefully to avoid potential delays or obstacles.
  3. Market Reaction:

    • The market's reaction to the merger would need to be managed carefully. Clear communication of the merger's strategic benefits would be crucial to gain investor support.

Conclusion

A strong argument can be made for Fluence Energy to consider merging with STEM Inc., based on the strategic alignment, operational efficiencies, financial benefits, and enhanced competitive position. However, it is essential to carefully evaluate and address potential challenges, particularly regarding integration and regulatory hurdles, to ensure a successful merger.

Sunday, June 30, 2024

This leader in synthetic biology, has developed several advanced technologies, like it's "foundry" that would attract takeover offers!

 


The Foundry is an automated biological engineering platform that integrates software, hardware, and wetware to design, build, and test organisms at a massive scale.

 Here are some key features:

  1. Automation and Robotics: The Foundry uses advanced automation and robotics to handle repetitive laboratory tasks, significantly speeding up the process of organism engineering.

  2. High-throughput Screening: This technology allows Ginkgo to test thousands of genetic designs simultaneously, optimizing the selection of the best-performing organisms.

  3. Machine Learning and AI: Ginkgo employs machine learning algorithms to predict the outcomes of genetic modifications, improving the accuracy and efficiency of their engineering processes.

  4. DNA Synthesis and Editing: The Foundry utilizes cutting-edge DNA synthesis and gene editing technologies, such as CRISPR, to precisely alter the genetic makeup of microorganisms.

  5. Data Integration and Bioinformatics: The platform integrates vast amounts of biological data, leveraging bioinformatics to gain insights and refine their engineering approaches continuously.

These capabilities enable Ginkgo Bioworks to create custom microorganisms for a wide range of applications, including the production of specialty chemicals, pharmaceuticals, food ingredients, and more. Their approach represents a significant advancement in the field of synthetic biology, pushing the boundaries of what is possible in organism engineering.

Could there be a merger of Ginkgo with another Synthetic Biology company?

Ginkgo Bioworks' "foundry" is one of the most enticing technologies for a merger offer in the synthetic biology (SynBio) space. Here are a few reasons why:

  1. High-Throughput Automation: Ginkgo's foundry is highly automated, which allows for the rapid design, building, and testing of biological systems. This high-throughput approach significantly accelerates the pace of research and development.

  2. Scalability: The foundry's automation and standardized processes enable scalable production of engineered organisms. This scalability is crucial for both research applications and commercial production.

  3. Data-Driven Insights: The foundry generates vast amounts of data that can be analyzed to gain insights and optimize biological designs. This data-driven approach enhances the precision and efficiency of synthetic biology projects.

  4. Cost Efficiency: By automating and standardizing the processes involved in synthetic biology, the foundry helps reduce costs associated with R&D. This cost efficiency is attractive to potential suitors looking to maximize their return on investment.

  5. Collaborative Potential: Ginkgo's foundry supports collaborations with a wide range of partners, from small biotech startups to large pharmaceutical companies. This collaborative potential can be a significant advantage in a merger, as it opens up new opportunities for joint ventures and shared projects.

  6. Innovative Edge: The foundry represents cutting-edge technology in synthetic biology, giving Ginkgo a competitive edge in the industry. This innovative edge can be highly appealing to a suitor looking to strengthen their technological capabilities.

While the foundry is a central component, other factors such as Ginkgo's intellectual property portfolio, customer base, and strategic partnerships would also be considered in a merger offer. However, the foundry's capabilities in automating and scaling synthetic biology processes make it a particularly attractive asset in the context of a takeover.

A potential takeover or buyout of Ginkgo Bioworks would likely attract interest from various companies, particularly those in the biotechnology, pharmaceuticals, and technology sectors. Here are some companies that could be well-positioned to consider such a move:

Biotechnology and Pharmaceutical Companies

  1. Bayer AG

    • Reason: Bayer has been expanding its focus on biotechnology, particularly in the agricultural sector. Ginkgo's expertise in synthetic biology could complement Bayer’s capabilities in crop science and pharmaceutical research.
  2. Roche

    • Reason: As a leader in personalized healthcare, Roche could benefit from Ginkgo's platform for developing customized biological solutions, potentially enhancing its drug discovery and diagnostics capabilities.
  3. Amgen

    • Reason: Amgen has a strong focus on biotechnology and innovation. Acquiring Ginkgo could enhance its research capabilities and support its pipeline of biologics and biosimilars.
  4. Novartis

    • Reason: With a commitment to innovation in pharmaceuticals, Novartis might see value in Ginkgo's platform to accelerate drug development and explore new therapeutic areas.

Technology Companies

  1. Alphabet (Google Health and Verily Life Sciences)

    • Reason: Alphabet’s investments in healthcare and life sciences align well with Ginkgo's capabilities. Verily and Google Health could leverage Ginkgo's synthetic biology platform to advance their healthcare solutions and technologies.
  2. IBM

    • Reason: IBM has been expanding its presence in healthcare and life sciences through AI and data analytics. Ginkgo's data-driven approach to biology could integrate well with IBM’s existing technologies.
  3. Microsoft

    • Reason: With its focus on AI and cloud computing in healthcare, Microsoft could benefit from Ginkgo's biological data and expertise to enhance its life sciences offerings.

Agricultural Companies

  1. Corteva Agriscience

    • Reason: As a major player in agriculture, Corteva could leverage Ginkgo's synthetic biology capabilities to develop new crop solutions and sustainable agricultural practices.
  2. Syngenta

    • Reason: Syngenta, focused on sustainable agriculture, might find strategic value in Ginkgo's ability to engineer microbes and other biological solutions for crop protection and enhancement.

Chemical Companies

  1. BASF
    • Reason: BASF’s interest in biotechnology for sustainable solutions could align well with Ginkgo's synthetic biology platform, potentially enhancing its product offerings in chemicals and materials.

Investment Firms and Private Equity

  1. SoftBank Vision Fund

    • Reason: SoftBank has a history of investing in technology-driven companies and might see Ginkgo as a strategic addition to its portfolio.
  2. Blackstone Group

    • Reason: As one of the largest private equity firms, Blackstone might consider acquiring Ginkgo to capitalize on its growth potential and innovation in synthetic biology.

Strategic Considerations

  • Partnership Synergies: Companies with existing partnerships or collaborations with Ginkgo might have an advantage in a buyout scenario. This includes companies that have invested in or partnered with Ginkgo for specific projects or innovations.

  • Market Expansion: Companies looking to expand their market presence in synthetic biology and biotechnology could find strategic value in acquiring Ginkgo to enhance their capabilities and product offerings.

  • Financial Capacity: The financial strength and investment capability of potential acquirers will play a significant role in determining their ability to pursue a buyout of Ginkgo Bioworks.

Conclusion

The best-positioned companies to acquire Ginkgo Bioworks are likely those with a strategic interest in synthetic biology and the financial capacity to support such a transaction. Given Ginkgo’s innovative platform and growth trajectory, any acquisition would be a significant strategic move for the acquirer.

At today's valuation, acquiring Ginkgo would be the equivalent of a rounding error for these companies!

Competitor, Twist Bioscience is a significant player in synthetic biology and biotechnology and could be considered a potential acquirer or merger partner for Ginkgo Bioworks. Here’s why Twist Bioscience might be a strategic fit:

Strategic Alignment

  1. Complementary Technologies:

    • Twist Bioscience specializes in DNA synthesis and provides high-quality synthetic DNA to various industries. This expertise complements Ginkgo Bioworks’ focus on synthetic biology and organism engineering. Together, they could enhance their capabilities in creating custom biological solutions for a wide range of applications.
  2. Expanded Product Offerings:

    • By combining their technologies, Twist and Ginkgo could offer a broader range of products and services, from DNA synthesis to complete synthetic biology solutions. This would enhance their ability to serve existing customers and attract new ones in sectors like pharmaceuticals, agriculture, and industrial biotechnology.
  3. Shared Market Goals:

    • Both companies are focused on advancing synthetic biology and expanding its applications across different industries. A partnership or merger could accelerate innovation and provide a competitive edge in the rapidly growing synthetic biology market.

Financial and Market Considerations

  1. Market Positioning:

    • Twist Bioscience is well-established in the synthetic DNA market and has a strong customer base. Combining forces with Ginkgo could strengthen their market position and create opportunities for cross-selling and up-selling products and services.
  2. Financial Synergies:

    • A merger or acquisition could result in cost synergies, such as reduced R&D expenses, shared facilities, and streamlined operations. This could improve profitability and financial performance for both companies.
  3. Valuation and Growth Potential:

    • The combined entity would likely be valued higher due to its increased capabilities and market reach. The growth potential in synthetic biology could attract more investors and lead to better financial performance.

Potential Challenges

  1. Integration Complexity:

    • Merging two companies with different operational structures and cultures can be challenging. It would require careful planning and execution to ensure a smooth integration and realize the potential synergies.
  2. Regulatory Considerations:

    • Any merger or acquisition in the biotech sector would need to navigate regulatory approvals and compliance requirements, which can be time-consuming and complex.

Conclusion

Twist Bioscience is indeed a logical candidate for acquiring or merging with Ginkgo Bioworks due to their complementary technologies, market goals, and potential for financial synergies. Such a move could create a powerhouse in the synthetic biology industry, capable of driving significant innovation and growth.

"The rapid and complete resolution of aggressive MSS colorectal cancer tumors observed in this study is unprecedented in the field" says the author Dr. Kasi


Thursday, June 27, 2024

I asked ChatGPT, What a merger between Twist Biosciences and Ginkgo Bioworks might do for the growth of Synthetic Biology!

 


A merger between Twist Bioscience and Ginkgo Bioworks would create significant synergies due to their complementary strengths in synthetic biology and biotechnology. Here’s a detailed breakdown of the potential synergies each company would bring:

Twist Bioscience:

  1. DNA Synthesis Technology:

    • Strength: Twist Bioscience is a leader in DNA synthesis technology, known for its high-throughput DNA synthesis platform.
    • Synergy: Ginkgo Bioworks could leverage Twist's efficient and scalable DNA synthesis capabilities to enhance its organism engineering processes, reducing time and costs associated with DNA synthesis.
  2. Innovation in Synthetic Biology:

    • Strength: Twist has developed novel technologies for gene synthesis, gene assembly, and sequencing.
    • Synergy: Combining these innovations with Ginkgo's expertise in organism design could accelerate the development of new synthetic biology applications and products.
  3. Broad Market Applications:

    • Strength: Twist serves various markets, including healthcare, industrial chemicals, agriculture, and data storage.
    • Synergy: This market diversity could complement Ginkgo’s applications, opening new avenues for revenue growth and diversification.
  4. Robust Intellectual Property Portfolio:

    • Strength: Twist holds numerous patents in the field of DNA synthesis and synthetic biology.
    • Synergy: The merger would enhance the combined entity’s IP portfolio, strengthening its competitive position and protecting its technological innovations.

Ginkgo Bioworks:

  1. Organism Engineering Expertise:

    • Strength: Ginkgo Bioworks is renowned for its organism engineering capabilities, designing custom microbes for various applications.
    • Synergy: Twist’s DNA synthesis could significantly improve the efficiency and success rate of Ginkgo's organism engineering projects.
  2. Automated Foundries:

    • Strength: Ginkgo operates automated foundries that scale the process of designing and testing organisms.
    • Synergy: Integrating Twist’s DNA synthesis into these foundries could streamline workflows and accelerate development cycles, leading to faster time-to-market for new products.
  3. Extensive Partner Network:

    • Strength: Ginkgo has established partnerships with numerous companies across various industries.
    • Synergy: These partnerships could provide new business opportunities for Twist’s technologies and products, leveraging Ginkgo’s established network for market expansion.
  4. Data and Machine Learning Capabilities:

    • Strength: Ginkgo utilizes advanced data analytics and machine learning to optimize organism design and development.
    • Synergy: Combining Twist’s high-throughput DNA synthesis data with Ginkgo’s data analytics capabilities could enhance predictive modeling and improve the accuracy of synthetic biology projects.

Combined Synergies:

  1. Enhanced R&D Capabilities:

    • The merger would create a powerhouse in synthetic biology, combining Twist’s cutting-edge DNA synthesis with Ginkgo’s organism engineering, leading to unprecedented R&D capabilities and innovation potential.
  2. Cost Efficiency and Scalability:

    • The integration of Twist’s scalable DNA synthesis with Ginkgo’s automated foundries could lead to significant cost savings and improved scalability for synthetic biology projects.
  3. Expanded Market Reach:

    • The combined entity could leverage Twist’s diverse market presence and Ginkgo’s extensive partnerships to penetrate new markets and applications, driving revenue growth and market share.
  4. Accelerated Time-to-Market:

    • Synergies in technology and process integration would enable faster development cycles, allowing the combined company to bring new products and solutions to market more rapidly.
  5. Stronger Competitive Position:

    • The merger would create a more robust and competitive entity in the synthetic biology space, with a comprehensive technology portfolio and a strong IP position.

Overall, a merger between Twist Bioscience and Ginkgo Bioworks would likely result in a powerful synergy that enhances technological capabilities, operational efficiencies, market reach, and competitive strength in the rapidly evolving field of synthetic biology.

Wednesday, December 4, 2013

Sirocco And Canada Lithium Combining To Form Strategic International Competitor In Growth-Oriented Industrial Minerals Sector

Toronto, Canada -- December 4, 2013

Sirocco Mining Inc. ("Sirocco") (TSX: SIM) and Canada Lithium Corp. ("Canada Lithium") (TSX: CLQ) (U.S. OTC: CLQMF) jointly announce that their respective boards of directors have approved, and that they have entered into, a definitive agreement (the "Arrangement Agreement") pursuant to which they will complete a business combination by way of a statutory Plan of Arrangement (the "Arrangement") under the Canada Business Corporations Act. Following the completion of the Arrangement, the current Canada Lithium shareholders will hold approximately 58% of the combined company, while current shareholders of Sirocco will hold approximately 42%.

 Highlights of the Arrangement Include:
 The business combination of Sirocco with its established Aguas Blancas iodine mine in Chile and Canada Lithium with its commissioning-stage lithium project in Quebec will create a significant industrial minerals producer in both the iodine and lithium markets. It is anticipated the combined company will provide significant market and growth synergies and over-all cost reduction. Sirocco's balance sheet and cash flow de-risk the production ramp-up of Canada Lithium's project. In addition, the combined company with its stronger balance sheet will offer greater cash resources. Anticipated ongoing growth in the automotive and electronics sector will continue to drive demand for lithium products, while anticipated increasing applications for X-ray media in Asia will continue to support iodine consumption. This allows for diversification of revenue and market risks.

 In the short to medium term, there is potential for downstream, value-added growth into lithium metal, potassium and sodium nitrates, sodium sulphate and lithium hydroxide. New and continued developments in the lithium battery sector, specifically lithium-iodine technology, which demonstrates higher energy levels and increased battery performance over current lithium battery technologies, may provide the combined company increased market opportunities as uptake of these new battery applications increases.

The combination of Canada Lithium and Sirocco results in only one of two public companies, the other being SQM of Chile, producing both iodine and lithium. Following the closing of the Arrangement, the current Sirocco management team will be appointed as officers of the combined company: Richard P. Clark, as Chief Executive Officer, Alessandro Bitelli, as Chief Financial Officer, Kevin Ross, as Chief Operating Officer and Hugh Stuart, as Vice President of Exploration. This is the core team that contributed to the growth of Red Back Mining's operations, which was acquired by Kinross Gold Corporation for $9.2 billion. Sirocco shareholders will receive 1.175 common shares (on a pre-consolidated basis) in the capital of Canada Lithium for each outstanding Sirocco common share. Pursuant to the transaction, Canada Lithium expects to issue approximately 294 million common shares (on a pre-consolidation and non-diluted basis). The Arrangement values each Sirocco share at C$0.48 representing a premium of approximately 23% to the 20-day volume weighted average price of the Sirocco common shares on the Toronto Stock Exchange as of December 3, 2013. The Arrangement has been approved by the board of directors of both companies. Following the closing of the Arrangement, the board of the combined company will be comprised of nine individuals. Four of the nine will be Canada Lithium nominees, with the remaining five individuals to be nominated by Sirocco. In connection with the Arrangement, Canada Lithium will consolidate its common shares on the basis of one post-consolidation common share for each three existing Canada Lithium common shares. "We're delighted to be joining forces with the Sirocco team. They have an exceptional track record in identifying growth opportunities, establishing sound operations and building wealth for shareholders," said Canada Lithium CEO Peter Secker. Commenting on the transaction, Sirocco CEO Richard Clark said: "We have been looking for growth opportunities in the industrial minerals sector and this combination provides an excellent opportunity for geographic and product diversification while at the same time aligning two products with potential future complementary applications."

At a full annualized production rate, Canada Lithium would produce approximately 20,000 tonnes of battery-grade lithium carbonate, which represents about 12% of the world's output. The commodity, an essential component in lithium-ion batteries, powers the vast and growing field of consumer electronics, electric and hybrid vehicles and grid storage units. Sirocco's iodine operation in Chile will produce approximately 1,400 tonnes of iodine in 2013, with plans to produce 1,000 tonnes in 2014. Upon completion of the installation of a semi-autogenous grinding (SAG) mill, annual capacity will increase to over 2,000 tonnes per annum. Under the Arrangement, as noted above, shareholders of Sirocco will receive 1.175 common shares (on a pre-consolidation basis) in the capital of Canada Lithium for each outstanding Sirocco common share, representing a premium of approximately 23% to the 20-day volume weighted average price of the Sirocco common shares on the Toronto Stock Exchange as of December 3, 2013. The total consideration payable pursuant to the Arrangement values Sirocco's equity at approximately C$120 million. Pursuant to the transaction, Canada Lithium expects to issue approximately 294 million common shares (on a pre-consolidation and non-diluted basis). The transaction will be carried out by way of a court-approved plan of arrangement and will require the approval of at least 66 2/3% of the votes cast by the securityholders of Sirocco at a special meeting of Sirocco shareholders expected to take place in January 2014. It is expected that the transaction will be exempt from the registration requirements of the U.S. Securities Act of 1933, as amended. The transaction is also subject to obtaining the approval of at least a majority of the votes cast by the shareholders of Canada Lithium approving the issuance of the shares in connection with the Arrangement and approval of at least 66 2/3% of the votes cast by the shareholders of Canada Lithium approving the consolidation of the shares of Canada Lithium on 3-for-1 basis, at a special meeting of Canada Lithium shareholders expected to take place the same date as the Sirocco meeting. In addition to securityholder and court approvals, the transaction is subject to applicable regulatory approvals, including the TSX, and the satisfaction of certain other closing conditions as is customary in transactions of this nature. Canada Lithium's financial advisor, Primary Capital Inc. has provided an opinion to the Canada Lithium board of directors that the transaction is fair, from a financial point of view, to Canada Lithium's shareholders (other than Sirocco). The financial advisor for Sirocco, Scotia Capital Inc., has provided an opinion to the Sirocco board of directors that the consideration to be received by the Sirocco shareholders under the transaction is fair, from a financial point of view, to the Sirocco shareholders. Canada Lithium's legal counsel is Cassels Brock & Blackwell LLP and Sirocco's legal counsel is Blake, Cassels & Graydon LLP. Kingsdale Shareholder Services Inc. has been retained as proxy solicitors and information agent. The Arrangement Agreement includes a commitment by each of Sirocco and Canada Lithium not to solicit alternative transactions to the proposed Arrangement. In certain circumstances, if a party terminates the definitive agreement to enter into an agreement to effect a superior proposal that is different from the Arrangement, then such party is obligated to pay to the other party as a termination payment of C$4 million, subject to a right by each party to match a competing superior proposal in question. In connection with the Arrangement Agreement, Sirocco has also agreed to provide a bridge loan of up to $10 million to Canada Lithium. The loan will be due and payable on the earliest of the following: (a) thirty days after the completion of a superior proposal transaction by Canada Lithium or (b) six months following a demand notice from Sirocco. The bridge loan is subject to, among other things, receipt of TSX approval and certain other closing conditions. The loan may be converted, at the option of Sirocco, into common shares of Canada Lithium at a conversion price of $0.399 per common share, at any time after the termination of the Arrangement Agreement. Further information regarding the transaction will be contained in an information circular that each of Canada Lithium and Sirocco will prepare, file and mail in due course to their respective shareholders in connection with the special meetings of each of the Canada Lithium and Sirocco shareholders to be held to consider the transaction. All shareholders are urged to carefully read the information circulars once they become available as they will contain additional important information concerning the transaction. Details regarding these and other terms of the transaction are set out in the Arrangement Agreement, which is available on SEDAR at www.sedar.com. The information agent for the Arrangement is Kingsdale Shareholder Services Inc. ("Kingsdale"). Questions and requests for assistance, including requests for additional information may be directed to Kingsdale at 1-866-581-0510 or by email at: contactus@kingsdaleshareholder.com. About Sirocco Sirocco Mining Inc. is a Canadian company which produces iodine from its Aguas Blancas mine in northern Chile. In addition, Sirocco has exploration interests in West Africa and is actively assessing other opportunities in the resource sector. For more information regarding Sirocco, please refer to Sirocco's public filings available at www.sedar.com and www.siroccomining.com including, in particular, Sirocco's Management's Discussion and Analysis for the year ended December 31, 2012 and its Annual Information Form for the year ended December 31, 2012 and the Management's Discussion and Analysis for the three-month and nine-month periods ended September 30, 2013. About Canada Lithium Canada Lithium holds a 100% interest in the Québec Lithium Project near Val d'Or, the geographical heart of the Québec mining industry. It has completed construction and is in the commissioning phase of an open-pit mine and on-site processing plant with estimated capacity to produce approximately 20,000 tonnes of battery-grade lithium carbonate annually. For more information regarding Canada Lithium, please refer to Canada Lithium's public filings available at www.sedar.com and www.canadalithium.com including, in particular, Canada Lithium's Management's Discussion and Analysis for the year ended December 31, 2012 and its Annual Information Form for the year ended December 31, 2012 and the Management's Discussion and Analysis for the three-month and nine-month periods ended September 30, 2013. Forward-Looking Statements Certain information contained in this news release, including any information relating to the proposed transaction (the "Transaction") and each issuer's future financial or operating performance may be deemed "forward-looking". These statements relate to future events or future performance and reflect each issuer's expectations regarding the Transaction, and the future growth, results of operations, business prospects and opportunities of Sirocco, Canada Lithium and the combined company. These forward-looking statements also reflect each issuer's current internal projections, expectations or beliefs and are based on information currently available to Sirocco or Canada Lithium, respectively. In some cases forward-looking information can be identified by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "projects", "potential", "scheduled", "forecast", "budget" or the negative of those terms or other comparable terminology. Assumptions upon which such forward looking information regarding completion of the Transaction are based include that Sirocco and Canada Lithium will be able to satisfy the conditions to the Transaction, that the required approvals will be obtained from the shareholders and optionholders of each issuer, as applicable, that all third party regulatory and governmental approvals to the Transaction will be obtained and all other conditions to completion of the Transaction will be satisfied or waived. Although Sirocco and Canada Lithium believe that the forward-looking information contained in this news release is based on reasonable assumptions, readers cannot be assured that actual results will be consistent with such statements. Accordingly, readers are cautioned against placing undue reliance on forward-looking information. Sirocco and Canada Lithium expressly disclaim any intention or obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise, except in accordance with applicable securities laws. For Further Information, Contact: Sophia Shane Sirocco Mining Inc. Tel: (604) 689-7842 Website: www.siroccomining.com Olav Svela Director, Investor Relations Canada Lithium Corp. Tel: (416) 479-4355 osvela@canadalithium.com

Thursday, August 23, 2012

Rockwood buys Talison Lithium for $724 Million Cash!

Talison Lithium Limited

TSX : TLH




August 23, 2012 08:15 ET

Cash Acquisition of Talison Lithium by Rockwood



PERTH, WESTERN AUSTRALIA--(Marketwire - Aug. 23, 2012) - Talison Lithium Limited ("Talison" or the "Company") (TSX:TLH) announced today that it has entered into a definitive Scheme Implementation Agreement ("SIA") with Rockwood Holdings, Inc. ("Rockwood") under which it is proposed that Rockwood, or a wholly-owned entity of Rockwood, will acquire 100% of the ordinary shares in the capital of Talison (the "Shares") by way of a Scheme of Arrangement ("Scheme") under the Australian Corporations Act 2001 (Cth) for cash consideration of C$6.50 per share. This values the equity of Talison at approximately C$724 million on a fully diluted basis.
The cash consideration of C$6.50 per Share, represents:
  • A 53% premium to Talison's last closing price on August 22, 2012 of C$4.24;
  • A 52% premium to Talison's 10 day volume weighted average price ("VWAP") of C$4.28; and
  • A 59% premium to Talison's 30 day VWAP of C$4.08.
The cash consideration provides an opportunity for Talison Shareholders to realise immediate value for their Shares at a substantial premium to market and reflects the size, strategic nature and growth potential of Talison's lithium operations.
The SIA entered into by Talison and Rockwood also proposes that Rockwood, or a wholly-owned entity of Rockwood, will acquire 100% of the options to acquire Shares ("Options") through an option scheme of arrangement ("Option Scheme") for cash consideration of C$6.50 per Option less the exercise price for that Option.
The board of directors of Talison ("Talison Directors") has considered the Scheme and the Option Scheme and unanimously recommends that Shareholders and Optionholders vote in favour of the Scheme and the Option Scheme, in the absence of a Superior Proposal (as defined in the SIA) and subject to an Independent Expert concluding that the Schemes are in the best interests of security holders. Each of the Talison Directors intends to vote the Shares and Options held or controlled by them in favour of the Scheme and Option Scheme.
Resource Capital Fund IV L.P. and Resource Capital Fund V L.P. (collectively, the "RCF Funds"), together having a 36.8% shareholding interest in Talison, have each confirmed to Talison that, in the absence of an offer which the RCF Funds determine is superior, they support the Scheme and intend to vote all of their Shares in favour of the Scheme.
Peter Robinson, Chairman of the Board of Talison, said, "Today marks a significant milestone in the history of Talison. Under the Scheme, Rockwood is offering cash consideration representing an attractive premium for Shareholders and allowing Shareholders to realise immediate value for their Talison Shares. This reflects positively on Talison's position in the global lithium market."
Macquarie Capital in Australia and Canada are acting as financial advisor to Talison. A special committee comprised of independent directors of Talison has received a fairness opinion from Macquarie Capital, effective on the date hereof, which provides that, subject to the assumptions and limitations contained therein, the consideration to be received by Shareholders pursuant to the Scheme is fair, from a financial point of view, to the Shareholders.
As Talison is an Australian incorporated company listed on the Toronto Stock Exchange, the Scheme will be implemented in accordance with the requirements of the Australian Corporations Act and any applicable Canadian requirements. Consistent with best practice in Australia, an Independent Expert will shortly be appointed to opine on whether the Scheme and the Option Scheme are in the best interests of Shareholders and Optionholders respectively.
Rockwood is a NYSE-listed global specialty chemicals and advanced materials company. Rockwood focuses on global niche segments of the specialty chemicals, pigments and additives and advanced materials markets.
The expectation of Talison's Directors is that Talison, as part of the Rockwood group, will continue to support its existing lithium concentrate customers in China and the rest of the world.
Scheme Details and Timetable
The completion of the Scheme and Option Scheme is subject to minimal conditions including:
  • Approval under the Australian Foreign Acquisitions and Takeovers Act 1975 (Cth);
  • Regulatory approvals from the Australian Securities and Investments Commission and the Australian Court;
  • Approval of the requisite majority of Talison Shareholders at a meeting of Shareholders;
  • No Material Adverse Change (as defined in the SIA) occurring to Talison; and
  • No Prescribed Occurrence (as defined in the SIA) occurring in relation to Talison.
Further due diligence is not a condition to completion of the Scheme or the Option Scheme.
The SIA contains terms typical for a transaction of this nature for an Australian incorporated company, including "no shop" and "no talk" provisions (subject to typical directors' fiduciary duty exemptions), notification and matching rights.
A mutual break fee ("Break Fee") of C$7 million is also payable in certain circumstances. Talison is not liable to pay the Break Fee by reason only of the Scheme not being approved by Talison shareholders or by the Australian Courts, nor in the event that Talison Directors withdraw their recommendation for the Scheme as a result of the Independent Expert finding that the Scheme is not in the best interests of Talison Shareholders. A Break Fee is payable by Rockwood if it materially breaches an obligation under the SIA and fails to remedy such breach. Any payment of the Break Fee will be in full and final satisfaction of all claims to which the party paying the break fee may be subject.
Implementation of the Scheme and the Option Scheme will also be subject to the terms and conditions set out in the Scheme and Option Scheme documentation when issued.
Further details are included in the executed SIA which is available on SEDAR at www.sedar.com and on the Talison website www.talisonlithium.com.
Scheme and Option Scheme booklets will be mailed to Shareholders and Optionholders. The booklets will contain, among other things, further information about the Scheme, the Option Scheme, a copy of the Independent Expert's report and related securityholder meeting materials. Talison expects that the approval of the Scheme and the Option Scheme will be put to Shareholders and Optionholders at meetings expected to be held in October 2012, and that the Scheme and Option Scheme will be completed shortly thereafter.
Advisors
Macquarie Capital is acting as financial advisor to Talison. Clayton Utz and Blake, Cassels & Graydon LLP are acting as legal advisors to Talison.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained in this press release, including any information as to Talison's mineral reserve and mineral resource estimates, strategy, projects, plans, prospects, future outlook, anticipated events or results or future financial or operating performance, may constitute "forward-looking information" within the meaning of Canadian securities laws. All statements, other than statements of historical fact, constitute forward-looking information. Forward-looking information can often, but not always, be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "predicts", "potential", "continue" or "believes", or variations (including negative variations) of such words, or statements that certain actions, events or results "may", "could", "would", "should", "might", "potential to", or "will" be taken, occur or be achieved or other similar expressions concerning matters that are not historical facts. The purpose of forward-looking information is to provide the reader with information about management's expectations and plans. Readers are cautioned that forward-looking statements are not guarantees of future performance. All forward-looking statements made or incorporated in this press release are qualified by these cautionary statements.
Forward-looking statements are necessarily based on a number of factors, estimates and assumptions that, while considered reasonable by Talison, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Such factors, estimates and assumptions include, but are not limited to: anticipated financial and operating performance of Talison, its subsidiaries and their respective projects; Talison's market position; future prices of lithium or lithium concentrates; estimation of mineral reserves and mineral resources; realization of mineral reserve and mineral resource estimates; timing, amount and costs of estimated future production; grade, quality and content of concentrate produced; sale of production; capital, operating and exploration expenditures; costs and timing of the expansion of the Greenbushes Lithium Operations; exploration and development of the Salares 7 lithium project; costs and timing of future exploration; requirements for additional capital; government regulation of exploration, development and mining operations; environmental risks; reclamation and rehabilitation expenses; title disputes or claims; absence of significant risks relating to Talison's mining operations; the costs of Talison's hedging policy; sales risks related to China; currency; interest rates, and limitations of insurance coverage. While Talison considers these factors, estimates and assumptions to be reasonable based on information currently available to it, they may prove to be incorrect and actual results may vary.
Readers are cautioned that forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Talison and/or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risk factors include, amount others, those described in the unaudited condensed consolidated interim financial statements of Talison and the related notes thereto as at March 31, 2012 and for the nine months ended March 31, 2012 and under the heading "Risk Factors" in the annual information form of Talison for the year ended June 30, 2011 dated September 23, 2011, each of which can be found on Talison's SEDAR profile at www.sedar.com. While Talison considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect and actual results may vary.
Although Talison has attempted to identify statements containing important factors that could cause actual actions, event or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking information contained herein is made as of the date of this press release based on the opinions and estimates of management on the date statements containing such forward-looking information are made. Except as required by law, Talison disclaims any obligation to update any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

Contact Information


Talison Lithium
Frank Wheatley
Executive Director
+1 (604) 985 0528
www.talisonlithium.com

Macquarie Capital
Michael Ashforth
Executive Director
+61 (8) 9224 0644

Macquarie Capital
David Cobbold
Managing Director
+1 (416) 848 3654
Enhanced by Zemanta